Inozyme Pharma Inc. announced that CEO and Chairman, Doug Treco, Ph.D., will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024. The chat will take place from 6:40-7:10pm ET / 3:40-4:10pm PT and can be accessed through the Investor Relations section of Inozyme’s website under events. A replay of the event will also be available for a limited time.
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company that is focused on developing novel therapeutics for the treatment of diseases affecting the vasculature, soft tissue, and skeleton. Currently, the company is working on an enzyme replacement therapy, INZ-701, which aims to address pathologic mineralization and intimal proliferation that can lead to severe health issues. INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
For more information about Inozyme Pharma or their ongoing clinical trials, visit their website at https://www.inozyme.com/ or follow them on LinkedIn, Twitter, and Facebook. Investors can contact Stefan Riley, Senior Director of IR and Corporate Communications at (857) 330-8871 or email stefan.riley@inozyme.com to learn more about investment opportunities with Inozyme Pharma Inc. Media inquiries can be directed to Matt Pera at SmithSolve by calling (973) 886-9150 or emailing matt.pera@smithsolve